|
1 |
Mon HC, Lee PC, Hung YP (洪逸平), Hung YW, Wu CJ, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. |
|
2 |
Huang BH, Li FY, Su SP, Chen CT, Chang KW, Yang MH (楊慕華), Chen MC, Chiang HK, Chan YH, Lee YJ. Integrating Ultrabright Polymer Dots and Stereo NIR-II Imager for Assessing Anti-Angiogenic Drugs in Oral Cancer Model. |
|
3 |
Ho WT, Chang JS, Lei CJ, Chen TC, Wang JK, Chang SW, Yang MH (楊慕華), Jou TS, Wang IJ. ROCK Inhibitor Enhances Resilience Against Metabolic Stress Through Increasing Bioenergetic Capacity in Corneal Endothelial Cells. |
|
4 |
Tang CY (唐振育), Lin YT, Yeh YC, Chung SY, Chang YC, Hung YP (洪逸平), Chen SC (陳三奇), Chen MH (陳明晃), Chiang NJ* (姜乃榕). The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer. |
|
5 |
Chung SY, Yeh YC, Huang CJ, Chiang NJ (姜乃榕), Hsu DS, Chan MH, Lu ML, Hsu TS, Hung YP (洪逸平), Yeh CN, Hsiao M, Chang YC, Wang YC, Chen MH* (陳明晃). Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma. |
|
6 |
Kao YC (高昀婕), Tsai YF, Shen SC, Dai MS, Chen FM, Liu LC, Chao TC (趙大中), Huang CC, Hou MF, Chen SC, Liu CY (劉俊宇), Tseng LM. Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer. |
|
7 |
Tseng YH, Tran TTM, Tsai Chang J, Huang YT, Nguyen AT, Chang IY, Chen YT, Hsieh HW, Juang YL, Chang PM (張牧新), Huang TY, Chang YC, Chen YM, Liu H, Huang CF. Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer. |
|
8 |
Lee CY, Yen HJ, Hou MH, Hung GY, Ho CY, Yu TY, Wu PK, Chen CM, Yen CC (顏厥全), Shiau CY, Chen PC, Wu HH, Wu CL, Chen WM. High dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma: A single institute experience in Taiwan. |
|
9 |
Peng HY, Chang CW, Wu PH, Li LJ, Lin YL, Hsiao M, Chang JY, Chang PM (張牧新), Lee HL, Chang WM. Oral Cancer-Derived miR-762 Suppresses T-Cell Infiltration and Activation by Horizontal Inhibition of CXCR3 Expression. Int J Mol Sci. 2025 Jan 26. ((IF:4.9 / Ranking:BIOCHEMISTRY & MOLECULAR BIOLOGY 66/313; CHEMISTRY, MULTIDISCIPLINARY 67/230) |
|
10 |
Hung YP (洪逸平), Lee PC, Chang YH, Yang MH (楊慕華), Chiu CH, Chen MH (陳明晃), Lan KH, Lee IC, Hou MC, Chao Y (趙毅), Huang YH. Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas. |
|
11 |
Chen SC (陳三奇), Ho HL, Liu CA, Hung YP (洪逸平), Chiang NJ (姜乃榕), Chen MH (陳明晃), Chao Y (趙毅), Yang MH* (楊慕華). PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma. |
|
12 |
Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, Li D, Zhukova L, Zhu AX, Chen MH (陳明晃), Hack SP, Wu S, Liu B, Guan X, Lu S, Wang Y, El-Khoueiry AB. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. |
|
13 |
Tsai YF, Lai JI (賴峻毅), Liu CY (劉俊宇), Hsi CN, Hsu CY, Huang CC, Feng CJ, Lin YS, Chao TC (趙大中), Chiu JH, Tseng LM. Correlation Between PIK3R1 Expression and Cell Growth in Human Breast Cancer Cell Line BT-474 and Clinical Outcomes. |
|
14 |
Teng HW (鄧豪偉), Huang HY, Lin CC, Twu YC, Yang WH, Lin WC, Lan HY, Lin YY, Hwang WL. CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. |
|
15 |
Piercey O, Chantrill L, Hsu HC, Ma B, Price T, Tan IB, Teng HW (鄧豪偉), Tie J, Desai J. Expert consensus on the optimal management of BRAF^V600E-mutant metastatic colorectal cancer in the Asia-Pacific region. |
|
16 |
Hung YP (洪逸平), Huang YH. Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution-Authors' Reply. |
|
17 |
Yang WH, Huang BY, Rao HY, Ye P, Chen B, Wang HC, Chung CH, Wu HH, Yen HR, Wang SC, Cha JH, Yan X, Yang MH* (楊慕華), Hung MC. Ribonuclease 1 Induces T-Cell Dysfunction and Impairs CD8+ T-Cell Cytotoxicity to Benefit Tumor Growth through Hijacking STAT1. |
|
18 |
Huang CJ, Liu GT, Yeh YC, Chung SY, Chang YC, Chiang NJ (姜乃榕), Lu ML, Huang WN, Chen MH* (陳明晃), Wang YC. Construction of hot tumor classification models in gastrointestinal cancers. |
|
19 |
Ho IW (何奕緯), Tseng YR, Liu CY (劉俊宇), Tsai YF, Huang CC, Tseng LM, Chao TC (趙大中), Lai JI* (賴峻毅). Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer. |
|
20 |
Lin TI, Tseng YR, Dong MJ, Lin CY, Chung WT, Liu CY (劉俊宇), Tsai YF, Huang CC, Tseng LM, Chao TC (趙大中), Lai JI* (賴峻毅). HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer. |
|
21 |
Ho YC, Chang MC, Lin WY (林妏霙), Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. |
|
22 |
Chou MY, Yang MH* (楊慕華). Immunomodulation on tumor immune microenvironment in acquired targeted therapy resistance and implication for immunotherapy resistance. |
|
23 |
Chen JS, Bai LY, Cheng HH, Chan SL, Zou JY, Shi X, Houchard A, Truong-Thanh XM, Chen MH* (陳明晃). Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan. |
|
24 |
Ho IW (何奕緯), Chiang NJ (姜乃榕), Lai JI (賴峻毅), Chang PM (張牧新), Chen SC (陳三奇), Hung YP (洪逸平), Chen MH* (陳明晃). Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma. |
|
25 |
Cheng WM, Li PC, Nguyen MT, Lin YT, Huang YT, Cheng TS, Nguyen TH, Tran TH, Huang TY, Hoang TH, Chen SY, Chu YC, Wu CW, Lee MF, Chiou YS, Liu HS, Hong YR, Chang PM (張牧新), Hu YF, Chang YC, Lai JM, Huang CF. Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions. |
|
26 |
Lai JI (賴峻毅), Jung KH, Shimizu C, Tiambeng ML, Tseng LM, Hsu DC, Ihm SY, Spiteri C, Tan EM, Qu S, Antill Y. Patients' and doctors' preferences in early-stage triple-negative breast cancer treatment in Asia-Pacific: a multi-territory discrete choice experiment using a cross-sectional survey. |
最後更新：